Leflunomide Elvim

Leflunomide, the active ingredient in Leflunomide Elvim, is an immunomodulatory agent presented as a tablet for oral use. It treats rheumatoid arthritis, psoriatic arthritis and juvenile idiopathic arthritis in adults and children as indicated.

GNH USA supplies Leflunomide Elvim as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease-modifying antirheumatic drug (DMARD) used in inflammatory arthritis conditions. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: improves skin and joint symptoms and limits disease progression. - Juvenile idiopathic arthritis: controls disease activity and helps maintain functional ability in pediatric patients.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: mild gastrointestinal upset. - Nausea: occasional feeling of sickness. - Elevated liver enzymes: transient increase in hepatic transaminases. - Hypertension: rise in blood pressure. - Rash: skin irritation or mild eruption.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Bone marrow suppression: anemia, leukopenia, thrombocytopenia. - Interstitial lung disease: pulmonary inflammation and fibrosis. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Leflunomide therapy, several safety considerations should be reviewed. - Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Liver function: assess baseline hepatic enzymes and monitor regularly. - Blood counts: perform complete blood count before treatment and periodically. - Infections: screen for active infections; avoid initiating during serious infection. - Teratogenicity: require effective contraception for both male and female patients during treatment and for a defined period after discontinuation. - Store at ambient temperature: keep tablets below 25 °C in the original container, protect from moisture and light.

Leflunomide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Methotrexate: combined use increases risk of hepatotoxicity. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): raise leflunomide plasma levels, heightening toxicity. - Warfarin: may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone marrow suppression. - Bupropion: may increase leflunomide concentrations modestly. - Live vaccines: reduced efficacy and potential infection risk.